← Back to Search

Other

ESK-001 Dose Level 1 for Plaque Psoriasis

Phase 2
Waitlist Available
Research Sponsored by Alumis Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial tests a new psoriasis treatment in patients to see if it's effective.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To compare the Psoriasis Area and Severity Index (PASI-75) between doses of ESK-001 and placebo
Secondary outcome measures
Heart rate
Psoriasis
To characterize the pharmacokinetics (PK) of ESK-001 (Cmax)
+1 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: ESK-001 Dose Level 5Experimental Treatment1 Intervention
ESK-001 administered as an oral tablet
Group II: ESK-001 Dose Level 4Experimental Treatment1 Intervention
ESK-001 administered as an oral tablet
Group III: ESK-001 Dose Level 3Experimental Treatment1 Intervention
ESK-001 administered as an oral tablet
Group IV: ESK-001 Dose Level 2Experimental Treatment1 Intervention
ESK-001 administered as an oral tablet
Group V: ESK-001 Dose Level 1Experimental Treatment1 Intervention
ESK-001 administered as an oral tablet
Group VI: PlaceboPlacebo Group1 Intervention
Placebo administered as an oral tablet
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ESK-001
2022
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Alumis IncLead Sponsor
5 Previous Clinical Trials
697 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At how many venues is this trial currently being conducted?

"Patients can enrol in this medical trial at 8 distinct clinical sites, such as Investigator Site # 1005 in Rolling Meadows, Investigator Site # 1015 in Houston, and Investigator Site # 1018 located in Los Angeles."

Answered by AI

Is this research initiative open to individuals who are above the age of fourty?

"This trial is only open to participants aged between 18 and 75. However, there are 31 other trials available for minors and 142 studies suitable for people over 65 years old."

Answered by AI

Are there still opportunities for people to participate in this trial?

"Affirmative. The details provided on clinicaltrials.gov point to the fact that this study is currently recruiting participants, which began on September 27th 2022 and was last updated October 27th 2022. Altogether, they are looking for 210 patients at 8 distinct sites."

Answered by AI

Is it possible to enlist in this medical research endeavor?

"The trial is attempting to enroll 210 individuals with psoriasis vulgaris between the age of 18-75, who weigh more than 40 kg (88 lb). Additionally, both genders must use reliable contraception throughout the duration of this study."

Answered by AI

What is the present size of the population being assessed in this clinical experiment?

"To commence this clinical trial, Alumis Inc requires 210 eligible participants. From Rolling Meadows, Illinois to Houston, Texas - the sponsor will be running experiments from various locations. Investigator Site # 1005 and Investigator Site # 1015 are among them."

Answered by AI

What deleterious effects have been reported when administering ESK-001 at Dose Level 5?

"Our assessment of the safety profile for ESK-001 Dose Level 5 was rated a 2, as there is some evidence indicating it is safe but none that point to its efficacy."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
Investigator Site #1027
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
2022. "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05600036.
~91 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top